This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
The CBCD congratulates Genocea Biosciences for entering phase 2 clinical trials of their new vaccine candidate against genital herpes, as reported on Marketwatch.com on July 21, 2014. (1)
Rochester, NY (PRWEB) August 17, 2014
The Center for the Biology of Chronic Disease (CBCD), congratulates Dr. Seth Hetherington, MD, chief medical officer of Genocea, and his research team, on entering phase 2 clinical trials of GEN-003, the companys immunotherapy (vaccine) candidate against herpes simplex-type 2 (HSV-2). Chip Clark, president and chief executive officer of Genocea said that We believe that there is a significant clinical need for an effective immunotherapy to treat HSV-2. Our market research supports that both patients and physicians would welcome a new treatment, such as GEN-003, with efficacy similar to oral antivirals, sustained duration of protection and enhanced convenience through simplified dosing. (1) The CBCD looks forward to seeing the results of the GEN-003 HSV-2 vaccine trials in 2015.
The CBCD further congratulates Genoceas researchers since HSV-2 is generally considered as a common chronic STD in both developed and developing countries with substantial morbidity. (See Interdisciplinary Perspectives on Infectious Disease, from May 27, 2014) (2) However, the Center reminds the public that approving a vaccine through the FDA may take time. Until then, the CBCD recommends two natural, safe and effective, HSV-2 remedies that are backed by clinical studies.
Click to learn more about genital herpes symptoms.
The Center for the Biology of Chronic Disease (CBCD) therefore recommends that people infected with the genital herpes virus (HSV-2) take Novirin or Gene-Eden-VIR. The formula of these natural antiviral products was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin and Gene-Eden-VIR formula is effective against the herpes simplex virus, and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, individuals infected with the HSV reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR. (3) The study authors also wrote that, we observed a statistically significant decrease in the severity, duration, and frequency of symptoms. (3)
Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.
Until now, drugs approved for the treatment of HSV-2 infections include penciclovir, acyclovir, famciclovir, and valaciclovir. However, their effectiveness is limited. For instance, a meta-analysis of five placebo-controlled and two dose comparison studies evaluated the effect of aciclovir, famciclovir or valaciclovir on symptoms. The meta-analysis showed that oral antiviral therapy decreases the duration and the associated pain of an outbreak by merely one day. (3) There are also natural remedies that target the latent HSV. Two of these clinically backed remedies are Novirin and Gene-Eden-VIR.
The CDC notes that Genital herpes is common in the United States. In the United States, about one out of every six people aged 14 to 49 years have genital herpes. You can get herpes by having vaginal, anal, or oral sex with someone who has the disease.
Fluids found in a herpes sore carry the virus, and contact with those fluids can cause infection. You can also get herpes from an infected sex partner who does not have a visible sore or who may not know he or she is infected because the virus can be released through your skin and spread the infection to your sex partner(s). (See the CDC, last updated July 1, 2014) (4)
There are currently no FDA approved vaccines against the genital herpes virus. Research shows that most drugs against HSV-2 only reduce outbreaks by one day. Thus, we recommend that infected individuals take Novirin or Gene-Eden-VIR, which are designed to help the immune system target the latent HSV-2. - Greg Bennett, CBCD
Interested individuals can view the two published studies on the Novirin and Gene-Eden-VIR formula here, http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.U-x7BeOSz90 and http://www.scirp.org/journal/PaperInformation.aspx?PaperID=44234
(1) Marketwatch.com - The Wall Street Journal - Genocea Commences Phase 2 Dose Optimization Trial for GEN-003 HSV-2 Immunotherapy. Published on July 21, 2014.
(2) Mehrabani D1, Behzadi MA2, Azizi S3, Payombarnia H3, Vahdani A3, Namayandeh M2, Ziyaeyan M2. Cervical Infection with Herpes simplex Virus, Chlamydia trachomatis, and Neisseria gonorrhoeae among Symptomatic Women, Dubai, UAE: A Molecular Approach. Interdiscip Perspect Infect Dis. 2014;2014:347602.
(3) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013. http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.U-x7BeOSz90
(4) CDC.com - Genital Herpes - CDC Fact Sheet. Last updated on July 1, 2014.
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/08/prweb12095337.htm
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.